

Piero Pollesello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/954500/publications.pdf>

Version: 2024-02-01

129
papers

5,835
citations

61984

43
h-index

82547

72
g-index

129
all docs

129
docs citations

129
times ranked

5804
citing authors

#	ARTICLE	IF	CITATIONS
1	Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. Journal of Magnetic Resonance Imaging, 1995, 5, 281-285.	3.4	340
2	Noninvasive in vivo quantitative assessment of fat content in human liver. Journal of Hepatology, 1997, 27, 108-113.	3.7	283
3	Levosimendan: Molecular mechanisms and clinical implications. International Journal of Cardiology, 2012, 159, 82-87.	1.7	256
4	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	7.1	182
5	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association“European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	2.2	171
6	Biochemical and immunohistochemical evidence that in cartilage an alkaline phosphatase is a Ca ²⁺ -binding glycoprotein.. Journal of Cell Biology, 1986, 103, 1615-1623.	5.2	146
7	Levosimendan Increases Diastolic Coronary Flow in Isolated Guinea-Pig Heart by Opening ATP-Sensitive Potassium Channels. Journal of Cardiovascular Pharmacology, 2001, 37, 367-374.	1.9	146
8	The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. International Journal of Cardiology, 2015, 191, 256-264.	1.7	125
9	Binding of Levosimendan, a Calcium Sensitizer, to Cardiac Troponin C. Journal of Biological Chemistry, 2001, 276, 9337-9343.	3.4	124
10	Levosimendan is a mitochondrial KATP channel opener. European Journal of Pharmacology, 2001, 428, 311-314.	3.5	117
11	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	7.1	115
12	The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. European Journal of Pharmacology, 2004, 486, 67-74.	3.5	105
13	Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. International Journal of Cardiology, 2016, 222, 303-312.	1.7	103
14	A role for the RISK pathway and K _{ATP} channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. British Journal of Pharmacology, 2008, 154, 41-50.	5.4	94
15	Pharmacological Mechanisms Contributing to the Clinical Efficacy of Levosimendan. Cardiovascular Drug Reviews, 2005, 23, 71-98.	4.1	91
16	Potassium-specific effects of levosimendan on heart mitochondria. Biochemical Pharmacology, 2004, 68, 807-812.	4.4	90
17	The contractile apparatus as a target for drugs against heart failure: Interaction of levosimendan, a calcium sensitizer, with cardiac troponin c. Molecular and Cellular Biochemistry, 2004, 266, 87-107.	3.1	90
18	Further Evidence for the Cardiac Troponin C Mediated Calcium Sensitization by Levosimendan: Structure-response and Binding Analysis with Analogs of Levosimendan. Journal of Molecular and Cellular Cardiology, 2000, 32, 479-491.	1.9	86

#	ARTICLE	IF	CITATIONS
19	Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. <i>International Journal of Cardiology</i> , 2015, 184, 323-336.	1.7	86
20	Inhibition of lipid peroxidation in isolated rat liver mitochondria by the general anaesthetic propofol. <i>Biochemical Pharmacology</i> , 1992, 44, 391-393.	4.4	84
21	The Cardioprotective Effects of Levosimendan: Preclinical and Clinical Evidence. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 50, 257-263.	1.9	81
22	Cellular UDP-Glucose Deficiency Caused by a Single Point Mutation in the UDP-Glucose Pyrophosphorylase Gene. <i>Journal of Biological Chemistry</i> , 1997, 272, 23784-23791.	3.4	77
23	Levosimendan meta-analyses: Is there a pattern in the effect on mortality?. <i>International Journal of Cardiology</i> , 2016, 209, 77-83.	1.7	77
24	Effects of Levosimendan and Milrinone on Oxygen Consumption in Isolated Guinea-Pig Heart. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 43, 555-561.	1.9	76
25	Complex electrophysiological remodeling in postinfarction ischemic heart failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3036-E3044.	7.1	72
26	Levosimendan Protection against Kidney Ischemia/Reperfusion Injuries in Anesthetized Pigs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 342, 376-388.	2.5	71
27	The levosimendan metabolite OR-1896 elicits vasodilation by activating the KATP and BKCa channels in rat isolated arterioles. <i>British Journal of Pharmacology</i> , 2006, 148, 696-702.	5.4	65
28	Renal Effects of Levosimendan: A Consensus Report. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 581-590.	2.6	65
29	ORM-10103, a novel specific inhibitor of the $\text{Na}^+/\text{Ca}^{2+}$ exchanger, decreases early and delayed afterdepolarizations in the canine heart. <i>British Journal of Pharmacology</i> , 2013, 170, 768-778.	5.4	65
30	Organic Solvent Systems for ^{31}P Nuclear Magnetic Resonance Analysis of Lecithin Phospholipids: Applications to Two-Dimensional Gradient-Enhanced ^1H -Detected Heteronuclear Multiple Quantum Coherence Experiments. <i>Analytical Biochemistry</i> , 1997, 245, 38-47.	2.4	64
31	Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. <i>British Journal of Pharmacology</i> , 2007, 150, 851-861.	5.4	62
32	Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice. <i>Journal of Cardiovascular Pharmacology</i> , 2018, 71, 1-9.	1.9	61
33	Oxygen-Derived Free Radical (ODFR) Action on Hyaluronan (HA), on Two HA Ester Derivatives, and on the Metabolism of Articular Chondrocytes. <i>Experimental Cell Research</i> , 1995, 218, 79-86.	2.6	60
34	The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. <i>International Journal of Cardiology</i> , 2016, 218, 150-157.	1.7	60
35	Structure of the 1-36 Amino-Terminal Fragment of Human Phospholamban by Nuclear Magnetic Resonance and Modeling of the Phospholamban Pentamer. <i>Biophysical Journal</i> , 1999, 76, 1784-1795.	0.5	56
36	Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus. <i>International Journal of Cardiology</i> , 2014, 174, 360-367.	1.7	56

#	ARTICLE	IF	CITATIONS
37	Calcium sensitizers: What have we learned over the last 25years?. International Journal of Cardiology, 2016, 203, 543-548.	1.7	56
38	Stereoselective binding of levosimendan to cardiac troponin C causes Ca ²⁺ -sensitization. European Journal of Pharmacology, 2004, 486, 1-8.	3.5	54
39	ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Current Opinion in Critical Care, 2004, 10, 436-441.	3.2	53
40	Structural determination of the acidic exopolysaccharide produced by a Pseudomonas sp. strain 1.15. Carbohydrate Research, 1999, 315, 159-168.	2.3	49
41	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of Cardiovascular Pharmacology, 2020, 76, 4-22.	1.9	49
42	Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. Journal of Molecular and Cellular Cardiology, 2003, 35, 1055-1061.	1.9	48
43	Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats. Liver Transplantation, 2014, 20, 361-375.	2.4	48
44	The Effect of a Novel Highly Selective Inhibitor of the Sodium/Calcium Exchanger (NCX) on Cardiac Arrhythmias in In Vitro and In Vivo Experiments. PLoS ONE, 2016, 11, e0166041.	2.5	47
45	Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application. Cardiovascular Drugs and Therapy, 2018, 32, 617-624.	2.6	46
46	Improved survival with simendan after experimental myocardial infarction in rats. European Journal of Pharmacology, 2001, 419, 243-248.	3.5	43
47	Two Inotropes With Different Mechanisms of Action: Contractile, PDE-Inhibitory and Direct Myofibrillar Effects of Levosimendan and Enoximone. Journal of Cardiovascular Pharmacology, 2005, 46, 369-376.	1.9	43
48	Preconditioning Effects of Levosimendan in a Rabbit Cardiac Ischemia-Reperfusion Model. Journal of Cardiovascular Pharmacology, 2006, 48, 148-152.	1.9	42
49	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology, 2019, 297, 83-90.	1.7	42
50	A Cellular UDP-glucose Deficiency Causes Overexpression of Glucose/Oxygen-regulated Proteins Independent of the Endoplasmic Reticulum Stress Elements. Journal of Biological Chemistry, 2004, 279, 21724-21731.	3.4	41
51	Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. ESC Heart Failure, 2017, 4, 595-604.	3.1	41
52	Structural and functional implications of the phospholamban hinge domain: impaired SR Ca ²⁺ uptake as a primary cause of heart failure. Cardiovascular Research, 2002, 56, 248-259.	3.8	40
53	Structure of the exopolysaccharide produced by Enterobacter amnigenus. Carbohydrate Research, 2005, 340, 439-447.	2.3	40
54	Effects of Levosimendan on the Energy Balance: Preclinical and Clinical Evidence. Journal of Cardiovascular Pharmacology, 2009, 53, 302-310.	1.9	40

#	ARTICLE	IF	CITATIONS
55	Solution Structure and Main Chain Dynamics of the Regulatory Domain (Residues 1â€“91) of Human Cardiac Troponin C. <i>Journal of Biological Chemistry</i> , 1998, 273, 15633-15638.	3.4	38
56	Selective Na^+ / Ca^{2+} exchanger inhibition prevents Ca^{2+} overloadâ€“induced triggered arrhythmias. <i>British Journal of Pharmacology</i> , 2014, 171, 5665-5681.	5.4	38
57	The Presence of Lys27 Instead of Asn27 in Human Phospholamban Promotes Sarcoplasmic Reticulum Ca^{2+} -ATPase Superinhibition and Cardiac Remodeling. <i>Circulation</i> , 2006, 113, 995-1004.	1.6	37
58	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. <i>Cardiac Failure Review</i> , 2020, 6, e19.	3.0	37
59	Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 73, 3-14.	1.9	36
60	Analysis of Total Lipid Extracts from Human Liver by ^{13}C and ^1H Nuclear Magnetic Resonance Spectroscopy. <i>Analytical Biochemistry</i> , 1996, 236, 41-48.	2.4	34
61	Energy state of chondrocytes assessed by ^{31}P -NMR studies of preosseous cartilage. <i>Biochemical and Biophysical Research Communications</i> , 1991, 180, 216-222.	2.1	33
62	Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. <i>Journal of Cardiovascular Pharmacology</i> , 2018, 71, 129-136.	1.9	33
63	Effect of Levosimendan and Milrinone on Regional Myocardial Ischemia/Reperfusion-Induced Arrhythmias in Dogs. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 129-135.	2.0	32
64	Effect of Levosimendan on Balance between ATP Production and Consumption in Isolated Perfused Guinea-Pig Heart before Ischemia or after Reperfusion. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, 316-321.	1.9	30
65	Hyaluronan Can Be Protected from Free-Radical Depolymerization by 2,6-Diisopropylphenol, a Novel Radical Scavenger. <i>Biochemical and Biophysical Research Communications</i> , 1993, 193, 927-933.	2.1	27
66	Cloning of the yeast ATP3 gene coding for the $\hat{3}$ -subunit of F1 and characterization of atp3 mutants.. <i>Journal of Biological Chemistry</i> , 1995, 270, 2880.	3.4	27
67	^{31}P NMR analysis of phospholipids in crude extracts from different sources: improved efficiency of the solvent system. , 1998, 36, 907-912.		27
68	Use of levosimendan in acute heart failure. <i>European Heart Journal Supplements</i> , 2018, 20, I2-I10.	0.1	27
69	Levosimendan Inhibits Peroxidation in Hepatocytes by Modulating Apoptosis/Autophagy Interplay. <i>PLoS ONE</i> , 2015, 10, e0124742.	2.5	26
70	Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. <i>International Journal of Cardiology</i> , 2017, 243, 389-395.	1.7	26
71	Regulation of total mitochondrial Ca^{2+} in perfused liver is independent of the permeability transition pore. <i>American Journal of Physiology - Cell Physiology</i> , 1999, 276, C1297-C1302.	4.6	22
72	Sensitivity of chondrocytes of growing cartilage to reactive oxygen species. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1998, 1425, 103-111.	2.4	21

#	ARTICLE	IF	CITATIONS
73	Conformations of the regulatory domain of cardiac troponin C examined by residual dipolar couplings. FEBS Journal, 2000, 267, 6665-6672.	0.2	21
74	Structural investigation of the exopolysaccharide produced by Pseudomonas flavescens strain B62 . Degradation by a fungal cellulase and isolation of the oligosaccharide repeating unit. FEBS Journal, 1998, 251, 971-979.	0.2	20
75	Positive Inotropic Effect of Levosimendan is Correlated to its Stereoselective Ca ²⁺ -Sensitizing Effect but not to Stereoselective Phosphodiesterase Inhibition. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 74-78.	2.5	20
76	Long-term effects of Na ⁺ /Ca ²⁺ exchanger inhibition with ORM-11035 improves cardiac function and remodelling without lowering blood pressure in a model of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2019, 21, 1543-1552.	7.1	20
77	¹ H-NMR Spectroscopic Studies of Lipid Extracts from Human Fatty Liver. Biochemical and Biophysical Research Communications, 1993, 192, 1217-1222.	2.1	19
78	Energy Metabolism, Replicative Ability, Intracellular Calcium Concentration, and Ionic Channels of Horse Articular Chondrocytes. Experimental Cell Research, 1994, 210, 130-136.	2.6	19
79	Inotropes and Inodilators for Acute Heart Failure. Journal of Cardiovascular Pharmacology, 2014, 64, 199-208.	1.9	19
80	Pharmaco-economics of levosimendan in cardiology: A European perspective. International Journal of Cardiology, 2015, 199, 337-341.	1.7	19
81	¹ H-NMR studies of lipid extracts of rat liver mitochondria. Biochemical and Biophysical Research Communications, 1991, 179, 904-911.	2.1	18
82	Lipid extracts from different algal species: ¹ H and ¹³ C-NMR spectroscopic studies as a new tool to screen differences in the composition of fatty acids, sterols and carotenoids. Journal of Applied Phycology, 1992, 4, 315-322.	2.8	18
83	³¹ P NMR studies of resting zone cartilage from growth plate. Magnetic Resonance in Medicine, 1992, 25, 355-361.	3.0	18
84	Prolonged Antispasmodic Effect in Isolated Radial Artery Graft and Pronounced Platelet Inhibition Induced by the Inodilator Drug, Levosimendan. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 269-274.	2.5	15
85	Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo. Pharmacological Reports, 2013, 65, 1304-1310.	3.3	15
86	Structure of the 1-36 N-Terminal Fragment of Human Phospholamban Phosphorylated at Ser-16 and Thr-17. Biophysical Journal, 2002, 83, 484-490.	0.5	14
87	Economic Evaluation of Levosimendan Versus Dobutamine for the Treatment of Acute Heart Failure in Italy. Advances in Therapy, 2012, 29, 1037-1050.	2.9	14
88	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure—Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. Journal of Clinical Medicine, 2019, 8, 1834.	2.4	14
89	An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. Expert Review of Cardiovascular Therapy, 2021, 19, 325-335.	1.5	14
90	Modification of plasma membrane of differentiating preosseous chondrocytes: Evidence for a degradative process in the mechanism of matrix vesicle formation. Experimental Cell Research, 1990, 188, 214-218.	2.6	13

#	ARTICLE	IF	CITATIONS
91	Efficacy of selective NCX inhibition by ORM-10103 during simulated ischemia/reperfusion. <i>European Journal of Pharmacology</i> , 2014, 740, 539-551.	3.5	13
92	Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1335-1347.	1.5	13
93	Levosimendan Improves Oxidative Balance in Cardiogenic Shock/Low Cardiac Output Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 373.	2.4	13
94	Novel Na ⁺ /Ca ²⁺ Exchanger Inhibitor ORM-10962 Supports Coupled Function of Funny-Current and Na ⁺ /Ca ²⁺ Exchanger in Pacemaking of Rabbit Sinus Node Tissue. <i>Frontiers in Pharmacology</i> , 2019, 10, 1632.	3.5	13
95	Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan. <i>Cardiac Failure Review</i> , 2019, 5, 155-161.	3.0	13
96	Analysis of Lipids in Crude Extracts by ¹³ C Nuclear Magnetic Resonance. <i>Analytical Biochemistry</i> , 1993, 214, 238-244.	2.4	12
97	Detection and quantitation of phosphorus metabolites in crude tissue extracts by ¹ H and ³¹ P NMR: use of gradient assisted ¹ H- ³¹ P HMQC experiments, with selective pulses, for the assignment of less abundant metabolites. <i>NMR in Biomedicine</i> , 1995, 8, 190-196.	2.8	12
98	Absence of mitochondrial activation during levosimendan inotropic action in perfused paced guinea pig hearts as demonstrated by modular control analysis. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2010, 299, R786-R792.	1.8	12
99	Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. <i>International Journal of Cardiology</i> , 2016, 215, 26-31.	1.7	12
100	Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 290, H2007-H2014.	3.2	10
101	Drug discovery and development for acute heart failure drugs: Are expectations too high?. <i>International Journal of Cardiology</i> , 2014, 172, 11-13.	1.7	10
102	Inotropic effect of NCX inhibition depends on the relative activity of the reverse NCX assessed by a novel inhibitor ORM-10962 on canine ventricular myocytes. <i>European Journal of Pharmacology</i> , 2018, 818, 278-286.	3.5	10
103	Potential of the Cardiovascular Drug Levosimendan in the Management of Amyotrophic Lateral Sclerosis: An Overview of a Working Hypothesis. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 389-399.	1.9	10
104	Differential effects of inotropes and inodilators on renal function in acute cardiac care. <i>European Heart Journal Supplements</i> , 2020, 22, D12-D19.	0.1	10
105	Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats. <i>European Journal of Pharmacology</i> , 2015, 750, 132-140.	3.5	9
106	Levosimendan-induced venodilation is mediated by opening of potassium channels. <i>ESC Heart Failure</i> , 2021, . .	3.1	9
107	Effects of Levosimendan on Inflammation and Oxidative Stress Pathways in a Lipopolysaccharide-Stimulated Human Endothelial Cell Model. <i>Biological Research for Nursing</i> , 2019, 21, 466-472.	1.9	7
108	Possible mechanism of inhibition of cartilage alkaline phosphatase by insulin. <i>Acta Diabetologica Latina</i> , 1989, 26, 321-327.	0.2	6

#	ARTICLE	IF	CITATIONS
109	1H- and 13C-NMR spectroscopic studies of lipid extracts of the red alga <i>Gracilaria longa</i> . <i>Journal of Applied Phycology</i> , 1992, 4, 149-155.	2.8	6
110	Hemodynamic Effects of Levosimendan in Outpatients With Advanced Heart Failure: An Echocardiographic Pilot Study. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, e36-e40.	1.9	6
111	ORM-3819 promotes cardiac contractility through Ca ²⁺ sensitization in combination with selective PDE III inhibition, a novel approach to inotropy. <i>European Journal of Pharmacology</i> , 2016, 775, 120-129.	3.5	5
112	Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case. <i>Journal of Medical Economics</i> , 2016, 19, 506-514.	2.1	5
113	Short-term treatments for acute cardiac care: inotropes and inodilators. <i>European Heart Journal Supplements</i> , 2020, 22, D3-D11.	0.1	5
114	Complete structure analysis of OR-1746, a complex product of cyclocondensation of arylhydrazomalnonitriles containing clusters of protonated and unprotonated nitrogens, by pulsed-field-gradient heteronuclear NMR. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 31, 125-131.	2.8	4
115	The clinical effects of levosimendan are not attenuated by sulfonylureas. <i>Scandinavian Cardiovascular Journal</i> , 2012, 46, 330-338.	1.2	4
116	The Novel Inodilator ORM-3819 Relaxes Isolated Porcine Coronary Arteries: Role of Voltage-Gated Potassium Channel Activation. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 218-224.	1.9	4
117	Levosimendan Comes of Age: 20 Years of Clinical Use. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 1-3.	1.9	4
118	Lessons from Lisbon on AHF drug treatment: Is it really true that all-old-failed-all-new-will-succeed?. <i>International Journal of Cardiology</i> , 2013, 168, 4798-4799.	1.7	3
119	Levosimendan in intensive care and emergency medicine: literature update and expert recommendations for optimal efficacy and safety. <i>Journal of Anesthesia, Analgesia and Critical Care</i> , 2022, 2, .	1.3	3
120	The Effect of Levosimendan during Long-Term Amiodarone Treatment in Dogs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 99, 27-32.	2.5	2
121	Discovery and Structural Characterization of a Phospholamban-Binding Cyclic Peptide and Design of Novel Inhibitors of Phospholamban. <i>Chemical Biology and Drug Design</i> , 2013, 81, 463-473.	3.2	2
122	Changed Relation between Phosphorylation Potential and Left Ventricular Developed Pressure in Guinea Pig Hearts during Ischemia-Reperfusion a. <i>Annals of the New York Academy of Sciences</i> , 1994, 723, 495-502.	3.8	1
123	Calcium Sensitizer Levosimendan and Its Use in Acute Heart Failure and Related Conditions. , 2008, , 595-607.		1
124	Levosimendan in Europe and China: An Appraisal of Evidence and Context. <i>European Cardiology Review</i> , 2021, 16, e42.	2.2	1
125	Levosimendan activates mitochondrial ATP-sensitive potassium channels. <i>Journal of Cardiac Failure</i> , 2004, 10, S92.	1.7	0
126	Facing up to the challenges of acute heart failure. <i>European Heart Journal Supplements</i> , 2020, 22, D1-D2.	0.1	0

#	ARTICLE	IF	CITATIONS
127	The inodilator levosimendan: 20 years of experience in various settings of cardiac care. Medical Research Journal, 2020, 5, 271-280.	0.2	0
128	Wound bed preparation for skin transplantation in chronic vein ulcers: A clinical case. Medical Research Journal, 0, , .	0.2	0
129	The adenylate cyclase activator forskolin potentiates the positive inotropic effect of the phosphodiesterase inhibitor milrinone but not of the calcium sensitizer levosimendan nor of its hemodynamically active metabolites. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, .	1.9	0